C. Puozzo

2.0k total citations
47 papers, 1.5k citations indexed

About

C. Puozzo is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, C. Puozzo has authored 47 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 14 papers in Pharmacology and 10 papers in Molecular Biology. Recurrent topics in C. Puozzo's work include Cancer Treatment and Pharmacology (22 papers), Pharmacogenetics and Drug Metabolism (14 papers) and Colorectal Cancer Treatments and Studies (9 papers). C. Puozzo is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Pharmacogenetics and Drug Metabolism (14 papers) and Colorectal Cancer Treatments and Studies (9 papers). C. Puozzo collaborates with scholars based in France, Italy and Germany. C. Puozzo's co-authors include Laurent Nguyen, F. Léger, Shari Lennon, B. E. Leonard, Dominique Deprez, Vittorio Gebbia, P. Fumoleau, Brigitte Tranchand, M. Marty and J. De Graeve and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

C. Puozzo

47 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Puozzo France 23 689 322 314 274 242 47 1.5k
Michel Lemaire Japan 28 952 1.4× 619 1.9× 223 0.7× 122 0.4× 203 0.8× 62 2.4k
Simon Joel United Kingdom 19 359 0.5× 652 2.0× 181 0.6× 95 0.3× 209 0.9× 36 1.7k
Peter Zannikos United States 19 204 0.3× 215 0.7× 178 0.6× 170 0.6× 121 0.5× 57 1.0k
Karen J. Klamerus United States 17 347 0.5× 500 1.6× 131 0.4× 382 1.4× 102 0.4× 41 1.3k
Christine Alvey United States 22 259 0.4× 268 0.8× 202 0.6× 107 0.4× 110 0.5× 46 1.4k
Markus Jerling Sweden 20 235 0.3× 283 0.9× 205 0.7× 94 0.3× 69 0.3× 44 1.3k
Bill J. Smith United States 20 697 1.0× 467 1.5× 162 0.5× 91 0.3× 39 0.2× 28 1.6k
Hélène M. Faessel United States 23 362 0.5× 1.1k 3.5× 87 0.3× 195 0.7× 208 0.9× 52 1.9k
Ryan M. Franke United States 16 554 0.8× 286 0.9× 53 0.2× 138 0.5× 240 1.0× 22 1.1k
Birk Poller Switzerland 20 684 1.0× 337 1.0× 86 0.3× 84 0.3× 41 0.2× 35 1.3k

Countries citing papers authored by C. Puozzo

Since Specialization
Citations

This map shows the geographic impact of C. Puozzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Puozzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Puozzo more than expected).

Fields of papers citing papers by C. Puozzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Puozzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Puozzo. The network helps show where C. Puozzo may publish in the future.

Co-authorship network of co-authors of C. Puozzo

This figure shows the co-authorship network connecting the top 25 collaborators of C. Puozzo. A scholar is included among the top collaborators of C. Puozzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Puozzo. C. Puozzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Briasoulis, Evangelos, Periklis Pappas, C. Puozzo, et al.. (2009). Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. Clinical Cancer Research. 15(20). 6454–6461. 77 indexed citations
3.
Lobert, Sharon & C. Puozzo. (2008). Pharmacokinetics, Metabolites, and Preclinical Safety of Vinflunine. Seminars in Oncology. 35(3 Suppl 3). S28–S33. 13 indexed citations
4.
Graeve, J. De, et al.. (2008). Metabolism pathway of vinorelbine (Navelbine®) in human: Characterisation of the metabolites by HPLC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 47(1). 47–58. 24 indexed citations
5.
Delord, Jean‐Pierre, et al.. (2007). Absolute bioavailability of an oral form of vinflunine, a first phase I trial. Molecular Cancer Therapeutics. 6. 1 indexed citations
6.
7.
Bourgeois, Hugues, Jan B. Vermorken, G. Dark, et al.. (2007). Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemotherapy and Pharmacology. 60(3). 407–413. 32 indexed citations
8.
Gralla, Richard J., et al.. (2007). Oral Vinorelbine in the Treatment of Non-Small Cell Lung Cancer. Drugs. 67(10). 1403–1410. 31 indexed citations
9.
Puozzo, C., P Hermann, & D Chassard. (2006). Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. International Clinical Psychopharmacology. 21(3). 153–158. 9 indexed citations
10.
Gebbia, Vittorio & C. Puozzo. (2005). Oral versus intravenous vinorelbine: clinical safety profile. Expert Opinion on Drug Safety. 4(5). 915–928. 51 indexed citations
11.
Nguyen, Laurent, et al.. (2004). I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplantation. 33(10). 979–987. 111 indexed citations
12.
Khayat, David, Olivier Rixe, R. Brunet, et al.. (2004). Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. Cancer Chemotherapy and Pharmacology. 54(3). 193–205. 23 indexed citations
13.
14.
Bennouna, Jaafar, P. Fumoleau, P. Armand, et al.. (2003). Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Annals of Oncology. 14(4). 630–637. 71 indexed citations
15.
Puozzo, C., E Panconi, & Dominique Deprez. (2002). Pharmacology and pharmacokinetics of milnacipran. International Clinical Psychopharmacology. 17. S25–S35. 60 indexed citations
16.
Marty, M., et al.. (2001). Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Annals of Oncology. 12(11). 1643–1649. 133 indexed citations
17.
Puozzo, C., et al.. (1998). Pharmacokinetics of milnacipran in liver impairment. European Journal of Drug Metabolism and Pharmacokinetics. 23(2). 273–279. 22 indexed citations
18.
Caron, Jacques, Christian Libersa, Dominique Lacroix, et al.. (1993). Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. European Neuropsychopharmacology. 3(4). 493–500. 10 indexed citations
19.
Assié, M.B., Marie Charvéron, Christiane Palmier, et al.. (1992). Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology. 31(2). 149–155. 38 indexed citations
20.
Cantfort, J. Van, J. De Graeve, & C. Puozzo. (1989). Differences in the metabolism of epicainide in rats and man. Xenobiotica. 19(1). 11–23. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michel Lemaire Breakdown of academic impact, for papers by Simon Joel Breakdown of academic impact, for papers by Peter Zannikos Breakdown of academic impact, for papers by Karen J. Klamerus Breakdown of academic impact, for papers by Christine Alvey Breakdown of academic impact, for papers by Markus Jerling Breakdown of academic impact, for papers by Bill J. Smith Breakdown of academic impact, for papers by Hélène M. Faessel Breakdown of academic impact, for papers by Ryan M. Franke Breakdown of academic impact, for papers by Birk Poller
Rankless by CCL
2026